News brief­ing: Gilead part­ner Gala­pa­gos sells off CRO for $37M; Polyphor bags $3.3M from CF Foun­da­tion

Close Gilead al­ly Gala­pa­gos is sell­ing off one of its con­tract re­search or­ga­ni­za­tions to a Pol­ish phar­ma com­pa­ny.

Gala­pa­gos has agreed to sell 100% of the out­stand­ing shares in the CRO Fi­delta to Selvi­ta, in a deal worth rough­ly $37 mil­lion ex­pect­ed to close in the first week of Jan­u­ary. The ac­qui­si­tion is ex­pect­ed to near­ly dou­ble Selvi­ta’s rev­enues, the com­pa­ny says, as well as ex­pand its drug dis­cov­ery ef­forts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.